PHAR

Pharming GroupA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$20.00

+62.9% vs current

Most likely

Base case

45%

Probability

Target price

$14.00

+14.0% vs current

B-

Bear case

30%

Probability

Target price

$9.00

-26.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

Packet evidence quality is low and uncertainty is high, so the tone stays cautious despite a positive directional prior. Primary company releases checked for this memo support improving Joenja commercial and regulatory momentum, but the overall setup is still a monitoring view because RUCONEST volatility, the pediatric CRL overhang, and limited external analyst-revision evidence reduce conviction. Headline buzz is medium due to recent earnings and regulatory updates, while social coverage was not provided as a usable signal.

RankAlpha Sentiment Codex - 2026-05-09

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-07eventU.S. pediatric Joenja label-expansion path resumesHigh impact

After the January 30, 2026 CRL, Pharming said it held a Type A meeting, resubmitted the pediatric sNDA for the 40 mg and 50 mg doses, and plans a separate summer 2026 filing for lower-dose patients; progress here matters because ages 4-11 are a meaningful identified APDS subgroup [#PR-2026-05-07].

2026-08-07eventEU Joenja decision window after positive CHMP opinionHigh impact

Pharming said the CHMP adopted a positive opinion for Joenja in APDS patients 12+ and that a final European Commission decision is expected in Q2 2026, creating a near-term regulatory catalyst for the first approved APDS treatment in the EU [#PR-2026-05-07].

2027-05-09catalystBroader leniolisib Phase II readouts could test the platform thesisHigh impact

Investor Day and the 1Q26 release both said Pharming expects top-line data in 2H 2026 from two Phase II trials of leniolisib in broader PIDs with immune dysregulation, including CVID, which would be the clearest proof point that Joenja can expand beyond APDS [#PR-2026-02-03] [#PR-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology